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Comparative in-vitro activities of quinupristin-dalfopristin against 
Gram-positive bloodstream isolates
Marinus A. Schouten and Jacomina A. A. Hoogkamp-Korstanje
Department o f Medical Microbiology, University Hospital St Radboud, PO Box 9101, 6500 HB Nijmegen, 
The Netherlands
The in-vitro activity of quinupristin-dalfopristin was compared with those of vancomycin, 
teicoplanin, erythromycin, clarithromycin, rifampicin, imipenem, meropenem, ciprofloxacin 
and sparfloxacin against 414 bloodstream isolates of Gram-positive cocci. Quinupristin- 
dalfopristin inhibited strains of Streptococcus pyogenes and Streptococcus agalactiae at
0.12 mg/L, methicillin- and/or erythromycin-resistant Staphylococcus aureus and Staphylo­
coccus epidermidis at 0.5 mg/L, Staphylococcus haemolyticus, Enterococcus faecium, 
Streptococcus pneumoniae, Streptococcus mltis, Streptococcus bovis, Streptococcus 
sanguis and Streptococcus anginosus at 1 mg/L and Enterococcus faecal/s at 8 mg/L.
Introduction
Quinupristin-dalfopristin is a streptogramin with signifi­
cant activity against Gram-positive cocci, including multi- 
resistant strains,1“3 and is therefore potentially useful 
for treating difficult infections.4 We compared the in- 
vitro activity of quinupristin-dalfopristin with that of 
vancomycin, teicoplanin, erythromycin, clarithromycin, 
rifampicin, imipenem, meropenem, ciprofloxacin and 
sparfloxacin against 414 bloodstream isolates of Gram- 
positive cocci.
Materials and methods
The bacterial strains were bloodstream isolates from 
patients hospitalized in the University Hospital St 
Radboud (392 strains), the Medical Centre Leeuwarden 
(20 strains) and the St Elisabeth Hospital Tilburg (two 
strains). Staphylococcus aureus ATCC 29213, Strepto­
coccus pneumoniae ATCC 46916 and Enterococcus 
faecalis ATCC 29212 were used as controls.
The antimicrobial agents tested were: quinupristin- 
dalfopristin and sparfloxacin (Rhone-Poulenc Rorer BV, 
Amstelveen, The Netherlands), ciprofloxacin (Bayer AG, 
Leverkusen, Germany), erythromycin and vancomycin 
(Sigma Chemie BV, Zwijndrecht, The Netherlands), 
teicoplanin (Hoechst Marion Merrel Dow, Amsterdam, 
The Netherlands), rifampicin (Yamanouchi BV, Delft, The 
Netherlands), clarithromycin (Abbott BV, Amstelveen, 
The Netherlands), imipenem (Merck Sharp and Dohme
BV, Haarlem, The Netherlands) and meropenem (Zeneca 
Farma BV, Ridderkerk, The Netherlands). Sterile water 
was used as the solvent for ciprofloxacin, vancomycin, 
teicoplanin, quinupristin-dalfopristin, imipenem and 
meropenem; ethanol for erythromycin and clarithromycin; 
methanol for rifampicin; and 0.1 M NaOH for sparfloxacin.
MICs were determined in duplicate by broth micro­
dilution5 with Isosensitest Broth (Oxoid CM 491) supple­
mented with 2% lysed horse blood for streptococci. The 
final inoculum size was 1.5-2.5 X 106 cfu/mL. The plates 
were incubated at 37°C and growth was assessed after 
24 h of incubation.
Results
The MI QoS and MIC90s of the antibiotics for the strains 
tested are shown in the Table.
Streptococci
S. pneumoniae strains were inhibited by quinupristin- 
dalfopristin at mg/L. The MICs of vancomycin were in 
the same range, while those of teicoplanin, the 
macrolides, rifampicin and imipenem were two- to four­
fold lower. The MICs of sparfloxacin were four-fold lower 
than those of ciprofloxacin.
Alpha-haemolytic streptococci, including Streptococcus 
mitis, Streptococcus bovis and Streptococcus anginosus 
were inhibited by quinupristin-dalfopristin at ^1 mg/L
4
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Table, MIC50, MIC90, ranges and per cent susceptibility of 414 
bloodstream isolates; breakpoints for susceptibility used were 
^1 mg/L for ciprofloxacin and sparfloxacin, and ^4 mg/L for the
other drugs
MIC (mg/L)
Strain MIC50 MIC90 range Susceptible (%)
S. pneumoniae (50)
vancomycin 0.25 0.5 0.25-0.5 100
teicoplanin 0.12 0.12 0.12 100
quinupristin-d alfopristin 0.5 0.5 0.12-1 100
erythromycin 0.12 0.12 0.12-1 100
clarithromycin 0.12 0.25 0.03-1 100
rifampicin 0.12 0.12 0.12-0.25 100
imipenem 0.12 0.12 0.12-0.25 100
meropenem 0.12 0.25 0.12-0.5 100
ciprofloxacin 2 2 0.5-4 40
sparfloxacin 0.5 0.5 0.25-1 100
S. pyogenes (20)
vancomycin 0.25 0.25 0.12-0.25 100
teicoplanin 0.12 0.12 0.12 100
quinupristin-dalfopristin 0.12 0.12 0.12 100
erythromycin 0.03 0.03 0.03 100
clarithromycin 0.03 0.03 0.03 100
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.12 0.12 100
meropenem 0.12 0.12 0.12 100
ciprofloxacin 0.25 0.5 0.25-2 95
sparfloxacin 0.25 0.5 0.12-0.5 100
S. agalactiae (25)
vancomycin 0.5 0.5 0.25-0.5 100
teicoplanin 0.12 0.12 0.12 100
quinupristin-dalfopristin 0.12 0.12 0.12 100
erythromycin 0.03 0.03 0.03 100
clarithromycin 0.03 0.03 0.03 100
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.12 0.12 100
meropenem 0.12 0.12 0.12 100
ciprofloxacin 0.5 1 0.25-1 100
sparfloxacin 0.25 0.5 0.12-0.5 100
MSSA (25)
vancomycin 0.5 1 0.5-1 100
teicoplanin 0.25 0.5 0.12-0.5 100
quinupristin-dalfopristin 0.25 0.5 0.12-0.5 100
erythromycin 0.12 0.12 0.06-0.25 100
clarithromycin 0.06 0.12 0.06-0.12 100
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.12 0.12 100
meropenem 0.12 0.12 0.12 100
ciprofloxacin 0.5 0.5 0.12-1 100
sparfloxacin 0.12 0.12 0.12-0.25 100
MRS A  (25)
vancomycin 0.5 1 0.25-1 100
teicoplanin 0.25 2 0.12-2 100
quinupristin-dalfopristin 0.25 0.5 0.12-0.5 100
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MIC (mg/L)
Strain MIC» MIQo range Susceptible
erythromycin 8 32 0.06-32 48
clarithromycin 2 32 0.06-32 56
rifampicin 0.12 1 0.06-32 92
imipenem 0.12 16 0.06-32 84
meropenem 0.25 16 0.12-32 84
ciprofloxacin 1 32 0.25-32 52
sparfloxacin 0.12 8 0.12-32 68
ERSA (24)
vancomycin 0.5 1 0.25-1 100
teicoplanin 0.5 1 0.12-2 100
quinupristin-dalfopristin 0.25 0.5 0.12-0.5 100
erythromycin 32 32 8-32 0
clarithromycin 32 32 2-32 12
rifampicin 0.12 32 0.12-32 79
imipenem 0.12 16 0.12-32 83
meropenem 0.12 16 0.12-32 83
ciprofloxacin 2 16 0.25-32 46
sparfloxacin 0.12 8 0.12-32 58
S. haemolyticus (25)
vancomycin 2 2 1-2 100
teicoplanin 2 8 1-32 84
quinupristin-dalfopristin 0.25 1 0.12-1 100
erythromycin 16 32 0.06-32 16
clarithromycin 8 32 0.06-32 20
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.5 0.12-32 96
meropenem 1 8 0.06-16 88
ciprofloxacin 16 32 0.25-32 12
sparfloxacin 8 16 0.12-32 24
S. epidermidis (25)
vancomycin 1 1 0.5-2 100
teicoplanin 0.5 1 0.12-2 100
quinupristin-dalfopristin 0.25 0.25 0.12-0.5 100
erythromycin 0.12 0.12 0.03-0.25 100
clarithromycin 0.06 0.06 0.03-0.12 100
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.12 0.12 100
meropenem 0.12 0.25 0.12-0.25 100
ciprofloxacin 0.25 0.5 0.12-2 96
sparfloxacin 0.12 0.25 0.12-0.25 100
MRSE (26)
vancomycin 1 1 1-2 100
teicoplanin 0.5 2 0.12-2 100
quinupristin-dalfopristin 0.12 0.25 0.12-0.25 100
erythromycin 32 32 0.06-32 38
clarithromycin 32 32 0.06-32 38
rifampicin 0.12 16 0.12-32 88
imipenem 0.12 16 0.12-32 88
meropenem 0.5 16 0.12-32 81
ciprofloxacin 0.5 32 0.25-32 54
sparfloxacin 0.12 16 0.12-16 54
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MIC (mg/L)
rain m ic 50 m ic 90 range Susceptibl
faecalis (25) 
vancomycin 1 4 0.5-4 100
teicoplanin 0.12 0.25 0.12-0.25 100
quinupristin-dalfopristin 4 8 4-8 80
erythromycin 32 32 0.12-32 48
clarithromycin 32 32 0.06-32 48
rifampicin 4 8 0.25-8 20
imipenem 1 2 1-2 100
meropenem 8 8 2-8 36
ciprofloxacin 1 32 0.5-32 56
Sparfloxacin 1 32 0.5-32 60
faecalisa (20)
vancomycin 1 1 0.25-2 100
teicoplanin 0.12 0.25 0.12-0.25 100
quinupristin-dalfopristin 4 8 4-16 55
erythromycin 32 32 32 0
clarithromycin 32 32 32 0
rifampicin 4 8 1-16 15
imipenem 2 2 0.5-4 100
meropenem 8 8 4-8 30
ciprofloxacin 32 32 0.5-32 5
Sparfloxacin 32 32 0.25-32 5
faecium (25)
vancomycin 0.5 1 0.5-1 100
teicoplanin 0.12 0.25 0.12-0.25 100
quinupristin-dalfopristin 0.5 1 0.25-1 100
erythromycin 32 32 1-32 36
clarithromycin 32 32 1-32 36
rifampicin 8 16 4-16 0
imipenem 32 32 32 0
meropenem 32 32 32 0
ciprofloxacin 8 32 0.5-32 4
Sparfloxacin 2 32 0.25-32 36
mitis (27)
vancomycin 0.5 0.5 0.12-1 100
teicoplanin 0.12 0.12 0.12 100
quinupristin-dalfopristin 0.5 1 0.12-1 100
erythromycin 0.12 8 0.03-32 85
clarithromycin 0.06 2 0.03-32 89
rifampicin 0.12 0.25 0.12-32 93
imipenem 0.25 0.25 0.12-2 100
meropenem 0.12 1 0.12-2 100
ciprofloxacin 2 8 0.25-16 33
Sparfloxacin 0.25 0.5 0.12-1 100
sanguis (25)
vancomycin 0.5 1 0.12-1 100
teicoplanin 0.12 0.12 0.12 100
quinupristin-dalfopristin 0.5 1 0.25-2 100
erythromycin 0.03 0.06 0.03-32 96
clarithromycin 0.03 0.12 0.03-32 96
rifampicin 0.12 0.12 0.12-0.25 100
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MIC (mg/L)
Strain MIC50 MIC90 range Susceptible (%)
imipenem 0.12 0.12 0.12-0.5 100
meropenem 0.12 0.12 0.12-0.5 100
ciprofloxacin 4 16 0.5-16 24
sparfloxacin 0.5 1 0.12-2 96
S. bovis (25)
vancomycin 0.5 0.5 0.25-1 100
teicoplanin 0.12 0.12 0.12-0.25 100
quinupristin-dalfopristin 0.5 1 0.12-1 100
erythromycin 0.03 32 0.03-32 84
clarithromycin 0.03 32 0.03-32 84
rifampicin 0.12 0.12 0.12 100
imipenem 0.12 0.12 0.12 100
meropenem 0.12 0.12 0.12 100
ciprofloxacin 1 2 1-4 68
sparfloxacin 0.5 1 0.25-1 100
S. anginosus (22)
vancomycin 1 1 0.5-32 91
teicoplanin 0.12 0.12 0.12-32 91
quinupristin-dalfopristin 0.5 1 0.25-1 100
erythromycin 0.03 0.12 0.03-0.5 100
clarithromycin 0.03 0.06 0.03-1 100
rifampicin 0.12 0.12 0.12-0.25 100
imipenem 0.12 0.12 0.12-2 100
meropenem 0.12 0.12 0.12—4 100
ciprofloxacin 0.5 1 0.12-8 91
sparfloxacin 0.5 1 0.12-2 91
a Highly gentamicin-resistant.
and Streptococcus sanguis at 2 mg/L. These MICs were in 
the same range as those of vancomycin and four- to eight­
fold higher than those of teicoplanin. The majority of 
S. mitis, S. sanguis, S. bovis and S. anginosus isolates were 
also inhibited by =^ 1 mg/L of rifampicin, imipenem, 
meropenem, sparfloxacin and the macrolides, some 
strains were resistant to the macrolides, ^50% of 
S. sanguis and 5. mitis isolates were inhibited at 2 mg/L 
of ciprofloxacin.
Beta-haemolytic streptococci, including Streptococcus 
pyogenes and Streptococcus agalactiae, were inhibited by 
quinupristin-dalfopristin and teicoplanin at 0.12 mg/L and 
by vancomycin at 0.25-0.5 mg/L. The MICs of the other 
drugs were in the same ranges, with the exception of 
ciprofloxacin.
Staphylococci
Methicillin-susceptible S. aureus (MSSA), methicillin-
resistant 5. aureus (MRSA) and erythromycin-resistant 
S. aureus (ERSA) isolates were inhibited by quinupristin- 
dalfopristin at 0.5 mg/L; the MRSA and ERSA isolates 
were inhibited by vancomycin and teicoplanin at 1-2 
mg/L. All other drugs inhibited MSSA isolates at low 
concentrations, but MICs for MRSA and ERSA were 
ten-fold higher or more.
Methicillin-susceptible Staphylococcus epidermidis 
(MSSE) and methicillin-resistant S. epidermidis (MRSE) 
isolates were inhibited by quinupristin-dalfopristin at 
^0.5 mg/L; quinupristin-dalfopristin was four times more 
active than vancomycin and teicoplanin. All other drugs 
inhibited MSSE at low concentrations, but MICs for 
MRSE were more than ten-fold higher. All isolates of 
Staphylococcus haemolyticus were inhibited by quinu- 
pristin-dalfopristin at =sl mg/L; the MICs of vancomycin 
and teicoplanin were two to eight times higher. The other 
drugs inhibited S. haemolyticus at varying concentrations, 
rifampicin at the lowest.
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Entero cocci
Enterococcus faecalis isolates, including highly genta- 
micin-resistant strains, were inhibited by quinupristin- 
dalfopristin at 8 mg/L, by vancomycin at 4 mg/L and 
by teicoplanin at 0.25 mg/L. All strains were inhibited 
by imipenem at 4 mg/L, about 50% of the susceptible 
E. faecalis strains were inhibited by the quinolones at 
1 mg/L. The other drugs showed moderate to poor effect. 
Enterococcus faecium was inhibited by quinupristin- 
dalfopristin and vancomycin at 1 mg/L, and by teicoplanin 
at 0.25 mg/L. Only a few strains were inhibited by 
sparfloxacin and the macrolides at clinically relevant 
concentrations.
Discussion
Worldwide emergence of resistant pneumococci, increase 
of enterococcal, streptococcal and staphylococcal infec­
tions in certain groups of patients and the widespread 
distribution of MRSA strains have limited the suitability 
of /?-lactams for empirical therapy and increased the need 
for alternatives. Quinupristin-dalfopristin exhibited high 
activity against many streptococci, E. faecium and staphy­
lococci including MSSA, MRSA, ERSA, MSSE, MRSE 
and S. haemolyticus. Many of our multiresistant S. epi- 
dermidis and S. haemolyticus strains were blood isolates 
from haematological patients with catheter-related infec­
tions. Vancomycin and teicoplanin, which are routinely 
used in these patients, pose a problem by their interaction 
with other nephrotoxic drugs. Quinupristin-dalfopristin 
may be an attractive alternative as this drug is not renally 
cleared and may not interact with cytotoxic drugs.
Penicillin-resistant pneumococci are still rare in The 
Netherlands. With the exception of ciprofloxacin, all 
drugs inhibited our strains at very low concentrations. 
The MICs of quinupristin-dalfopristin fitted well with the 
results of others.2 It has been estimated that 40% of 
pneumococci are now susceptible to ciprofloxacin, 
compared with 80% before ciprofloxacin was introduced,6 
reflecting the selective pressure caused by widespread 
use. Vancomycin, teicoplanin or macrolides, usually in 
combination with an aminoglycoside, are well-known 
treatments used for endocarditis when penicillins are 
contra-indicated or have failed. Most of our S. bovis,
5. sanguis and S. mitis isolates were from patients with 
endocarditis. In comparative studies the activity of quinu­
pristin-dalfopristin against some viridans streptococci was 
similar to that of macrolides.3,7 This study showed that 
quinupristin-dalfopristin, imipenem and meropenem 
could inhibit all 77 strains tested at very low concentra­
tions, whereas not all strains were susceptible to 
macrolides or rifampicin. Carbapenems and quinu­
pristin-dalfopristin may therefore be interesting alterna­
tives as new, potent, non-toxic combinations for the 
treatment of endocarditis.
We have found that most E. faecium strains were resis­
tant to macrolides, quinolones and carbapenems.8 We 
also observed an increase in MIC with time: 100% 
were susceptible before ciprofloxacin was introduced6 
compared with 56% at present. Like others, we found 
that E. faecalis was less susceptible to quinupristin- 
dalfopristin than E. faecium , 3 , 9  although 80% of E. fae­
calis and 55% of the highly resistant strains were sus­
ceptible to ^4 mg/L. No vancomycin-resistant isolates 
were found, so vancomycin and teicoplanin may remain 
first choice agents for enterococcal infections and quinu­
pristin-dalfopristin may be kept for the treatment of 
vancomycin-resistant isolates.
In conclusion, quinupristin-dalfopristin shows promis­
ing in-vitro activity and may be a welcome drug in the 
therapy of methicillin-resistant staphylococcal infections 
and infections by viridans streptococci and resistant 
enterococci.
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